FDA-drug screening identifies deptropine inhibiting hepatitis E virus involving the NF-κB-RIPK1-caspase axis by Qu, C. (Changbo) et al.
Contents lists available at ScienceDirect
Antiviral Research
journal homepage: www.elsevier.com/locate/antiviral
FDA-drug screening identiﬁes deptropine inhibiting hepatitis E virus
involving the NF-κB-RIPK1-caspase axis
Changbo Qua,b, Yang Lib, Yunlong Lib, Peifa Yub, Pengfei Lib, Joanne M. Donkersc,
Stan F.J. van de Graafc, Robert A. de Manb, Maikel P. Peppelenboschb, Qiuwei Panb,∗
a The Key Laboratory of Molecular Microbiology and Technology, Ministry of Education, TEDA Institute of Biological Sciences and Biotechnology, Nankai University,
Tianjin, PR China
bDepartment of Gastroenterology and Hepatology, Erasmus MC-University Medical Center, Rotterdam, the Netherlands
c Amsterdam UMC, University of Amsterdam, Tytgat Institute for Liver and Intestinal Research, Amsterdam Gastroenterology and Metabolism, Amsterdam, the Netherlands
A R T I C L E I N F O
Keywords:
HEV
NF-κB signaling
RIPK1
Caspase
Deptropine
A B S T R A C T
Hepatitis E virus (HEV) infection is the leading cause of acute hepatitis worldwide and can develop into chronic
infection in immunocompromised patients, promoting the development of eﬀective antiviral therapies. In this
study, we performed a screening of a library containing over 1000 FDA-approved drugs. We have identiﬁed
deptropine, a classical histamine H1 receptor antagonist used to treat asthmatic symptoms, as a potent inhibitor
of HEV replication. The anti-HEV activity of deptropine appears dispensable of the histamine pathway, but
requires the inhibition on nuclear factor-κB (NF-κB) activity. This further activates caspase mediated by receptor-
interacting protein kinase 1 (RIPK1) to restrict HEV replication. Given deptropine being widely used in the
clinic, our results warrant further evaluation of its anti-HEV eﬃcacy in future clinical studies. Importantly, the
discovery that NF-κB-RIPK1-caspase pathway interferes with HEV infection reveals new insight of HEV-host
interactions.
1. Introduction
Acute liver inﬂammation is usually self-limiting upon elimination of
the etiological agents. However, unresolved inﬂammation may lead to
the development of chronic liver diseases and cancer. Hepatitis E virus
(HEV) infection represents the most common cause for acute viral he-
patitis (Crossan et al., 2014). It has caused many large hepatitis out-
breaks, especially in resource-limited regions (Hakim et al., 2018). In
the developing countries, the major clinical burden lies with the preg-
nant women population, which is usually caused by genotype 1 HEV. If
no recovery from spontaneous clearance of the virus, these acutely in-
fected patients will have high risk to develop liver failure and death. In
western counties, chronic hepatitis E cases have been frequently re-
ported in immunocompromised patients, in particular organ transplant
recipients (Kamar et al., 2008). Genotype 3 and occasionally genotype 4
HEV are the main causes of chronic infection. For the infection in these
speciﬁc populations including pregnant women and organ transplan-
tation patients, safe and eﬀective antiviral treatment is evidently re-
quired.
Besides supportive care, pegylated interferon alpha (PEG-IFNα) and
ribavirin (Kamar et al., 2014) in particular have been explored in the
clinic for treating some chronic HEV cases. Ribavirin is eﬀective in
general, but the failure of treatment has been frequently reported
(Debing et al., 2016). However, the remaining challenges include that
not all chronic HEV patients respond to ribavirin, the emerging of po-
tential resistance strains and the substantial side eﬀects that limit the
applications in pregnant women, young children and elderly patients
(Todt et al., 2016). Sofosbuvir, a clinically used direct-acting antiviral
for treating hepatitis C virus (HCV) infection, has recently been pro-
posed for treating HEV. However, mixed results were obtained from
both experimental models and patients (Dao Thi et al., 2016; Kamar
et al., 2017), and likely it is not very eﬀective against HEV (Kamar
et al., 2017). In parallel, various preclinical compounds, including nu-
cleoside and non-nucleoside antiviral agents (Netzler et al., 2019),
protein kinase-targeted compounds (Wang et al., 2017a), inhibitors
targeting mitochondrial metabolism (Qu et al., 2019), inhibitors of
nucleotide synthesis (Wang et al., 2016) and natural compounds (Todt
et al., 2018), are being investigated in experimental models. Given the
pathogenic nature and the speciﬁc populations aﬀected by HEV, we
hypothesize that repurposing currently used drugs represents an ef-
fective approach to develop antiviral treatment that can readily beneﬁt
the patients.
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In this study, we screened a library of FDA-approved drugs. We
identiﬁed deptropine, a traditional histamine receptor H1 antagonist
used to treat asthmatic symptoms (de Vries et al., 2006; Schirm et al.,
2002), as a potent inhibitor against HEV. Mechanistically, the anti-HEV
activity of deptropine is dispensable of the histamine pathway, but
requires the crosstalk between nuclear factor-κB (NF-κB) and caspase
activity regulated by receptor-interacting protein kinase 1 (RIPK1).
These results bears potential implications for the real-world treatment
of HEV patients from developing to developed countries with acute or
chronic infection.
2. Materials and methods
2.1. Drug screening
A commercially available library of FDA-approved drugs, the
Prestwick chemical library (http://www.prestwickchemical.com/), was
used. The screening was performed in a 96-well plate format with
10,000 cells in each well. Compounds were solubilized at 1mM in di-
methyl sulfoxide (DMSO) and all compounds were diluted in culture
media for a ﬁnal concentration of 10 μM during screening.
2.2. Cell culture models
Multiple cell lines including human hepatoma Huh7.5 cell line,
Hep3B cell line and human embryonic kidney epithelial HEK 293T cell
line were kindly provided from Department of Viroscience, Erasmus
Medical Center. These cell lines were cultured with Dulbecco's modiﬁed
Eagle medium (DMEM) (Lonza Biowhittaker, Verviers, Belgium) sup-
plemented with 10% (vol/vol) heat-inactivated fetal calf serum (FCS)
(Hyclone, Lonan, Utah), 100 IU/mL penicillin, 100 μg/mL strepto-
mycin. Mouse embryonic ﬁbroblast (MEF) WT and NF-κB −/− cells
were generated by Dr. A. Hoﬀmann (Signaling Systems Lab, Los
Angeles, CA), and were grown in DMEM with 10% FCS, 100 IU/mL
penicillin, 100 μg/mL streptomycin, 2 mM L-glutamine and 20mM
HEPES as described previously (Xu et al., 2017).
For genotype 3 HEV models, Huh7.5, Hep3B, and 293T cell lines
were electroporated with the subgenomic HEV RNA (p6 clone) coupled
with a Gaussia luciferase reporter gene to establish the replication
model (subgenomic replicon). Electroporation of the full-length p6 HEV
genome was used to establish the infectious model, and more details
have been described previously (Wang et al., 2017b). MEF cells were
seeded in 96 well plate (1×104 per well) and were inoculated with cell
culture-produced HEV particles (1.5× 106 HEV RNA copies/ml) for
48 h before being subjected to qRT-PCR analysis.
For HEV genotype 1 replicon model, Huh7.5 cells were electro-
porated with Sar 55/S17/luc HEV RNA, and viral replication was de-
tected by Gaussia luciferase activity (Xu et al., 2017). For HCV replicon
model, Huh7.5 cells were electroporated with the subgenomic HCV
bicistronic replicon (I389/NS3–3V/LucUbiNeo-ET), and viral replica-
tion was monitored by measuring ﬁreﬂy luciferase activity (Pan et al.,
2009). For rotavirus model, Caco 2 cells were inoculated with simian
rotavirus SA11. NF-κB, AP-1 luciferase reporter cells were generated by
transducing Huh7.5 cells with lentiviral vectors expressing the ﬁreﬂy
luciferase gene under the control of the promoters containing the NF-
κB, AP-1 motifs (Wang et al., 2017a), respectively (System Biosciences).
2.3. Statistical analysis
Statistical analysis was performed using the nonpaired, nonpara-
metric test with Mann-Whitney test (GraphPad Prism version 5.01;
GraphPad Software). P values < 0.05 were considered statistically
signiﬁcant. (See Supplemental Information for more detailed methods).
Fig. 1. Screening of a drug library identiﬁed deptropine as a potent inhibitor of HEV replication. (A) Schematic illustration of the screening strategy. The primary
screening was conducted in the HEV replicon model, and the eﬀects of selected primary hits was further evaluated in the HEV infectious model. (B) Huh7.5 cell based
HEV replicon model was treated with 1280 compounds with 95% of FDA-approved drugs at 10 μM. The HEV-related Gaussia luciferase value (HEV RLU) was
measured 48 h post-treatment. Points represent the relative HEV replication for each drug. (C) qRT-PCR analysis of HEV viral RNA level in Huh7.5 cell based HEV
infectious model treated with the 38 selected drugs at 5 μM from the primary screening for 48 h. Data were normalized to the DMSO vehicle control (set as 1) and
presented in dot plots. The black dot pointed by an arrow represents deptropine.
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3. Results
3.1. Screening of a library of FDA-approved drugs identiﬁes deptropine as a
potent Anti-HEV agent
To identify potential anti-HEV drug candidates, we employed a li-
brary of 1280 compounds (95% are FDA-approved drugs). The initial
screening was performed in a Huh7.5 cell-based genotype 3 HEV re-
plicon model in which the 5’ portion of HEV ORF2 was replaced with
the in-frame secreted form of Gaussia luciferase. Thus, accumulation of
luciferase indicates viral replication, whereas the absence of the ORF2,
which encodes the capsid protein precludes the propagation of novel
viral particles. This model was treated with each compound at a con-
centration of 10 μM and the DMSO vehicle control for 48 h (Fig. 1A).
We found that some drugs inhibit but some promote, whereas the
majority have no major eﬀect on HEV replication-related luciferase
activity (Fig. 1B). To exclude the possibility that the antiviral ability
may be attributed to its cytotoxicity (Fig. S1), 38 drugs identiﬁed with
more than 50% inhibition on HEV replication-related luciferase activity
and less than 50% cytotoxicity were selected (Supplementary Table 1).
Their antiviral eﬀects were further investigated at lower concentration
(5 μΜ) in the full-length HEV infectious model by quantifying the HEV
RNA using qRT-PCR assay (Fig. 1C). In both models, deptropine showed
the most potent anti-HEV eﬀects and thus was subjected to further
detailed study.
3.2. Deptropine inhibits HEV in multiple cell models
Since HEV can cause a wide range of extrahepatic manifestations,
we further validated the antiviral eﬀect in several other cell models,
including hepatic and nonhepatic cell lines. In line with the results
observed in Huh7.5 cell model (Fig. 2A), deptropine dose-dependently
inhibited HEV replication in HEK293T (Fig. 2B) and Hep3B cells (Fig.
S2A). Of note, in the Hep3B cell model, treatment with 5 μM deptropine
potently inhibits HEV without aﬀecting cell viability, excluding the
antiviral eﬀect of deptropine is through nonspeciﬁc cytotoxicity. The
50% inhibition and cytotoxicity (IC50 and CC50) concentrations of
deptropine were 2.89 μM and 12.20 μM in Huh7.5 cells, and 0.84 μM
and 18.64 μM in HEK293T cells. Interestingly, genotype 1 HEV replicon
is more sensitive to deptropine with an IC50 of 0.49 μM in Huh7.5 cells
(Fig. 2C). The anti-HEV eﬀect of deptropine was further veriﬁed by the
re-infection assay (Fig. S2E). In addition, we found that deptropine
signiﬁcantly reduced the secretion of HEV into the supernatant (Fig.
S2F).
We next examined the eﬀect of long-term treatment as described
previously (Qu et al., 2017). Treatment with 5 μM deptropine drama-
tically reduced HEV viral RNA by 80% after 39 days, and this eﬀect was
further conﬁrmed at ORF2 protein level (Fig. 2D). We further evaluated
whether deptropine has a broad antiviral activity and found that dep-
tropine potently inhibits HCV (Fig. S2C) but not rotavirus (Fig. S2D)
replication.
3.3. Histamine H1 receptor is dispensable for the Anti-HEV activity of
deptropine
Because deptropine is a well-characterized histamine H1 receptor
antagonist, we investigated whether this receptor is involved in its anti-
HEV eﬀect. We found that the expression of the H1 receptor was hardly
detectable in both Huh7.5 and 293T cells (Fig. S3A), which is consistent
with a previous study showing that Huh7.5 cells are deﬁcient of this
receptor (Pietschmann, 2017). Diphenhydramine, another H1 antago-
nist (Fig. 3A), exerted no inhibitory eﬀect on HEV in both Huh7.5 and
293T cells (Fig. 3B). Chlorcyclizine HCl (CCZ), an H1 antagonist that
has been shown to block HCV entry (He et al., 2015), also could not
inhibit HEV (Fig. 3C and Fig. S3B), or HCV replication in a subgenomic
replicon model (Fig. S3B). These results collectively suggest that the
inhibitory eﬀect of deptropine on HEV replication is likely dispensable
of H1 receptor-mediated pathway.
Since we have detected the expression of other histamine receptors
to some extent, we performed a competition assay by co-incubating
deptropine with histamine in the replicon model to assess the possible
involvement of these receptors. We found that histamine has no eﬀect
on either HEV replication or deptropine-induced inhibition of HEV re-
plication. Surprisingly, in the infectious model, histamine was able to
inhibit HEV and slightly attenuated the anti-HEV eﬀect of deptropine
(Fig. 3D). Taken together, these results indicate that deptropine po-
tently inhibits HEV replication independent of the histamine signaling,
whereas we do not fully exclude that the histamine signaling may in-
terfere with the other steps of HEV life cycle, such as viral entry. Be-
cause benztropine, a chemically similar drug with deptropine (Cui
et al., 2017), has been shown to exert its eﬀect through alpha-7 nico-
tinic receptor (α7 receptor) and expression of this receptor has been
reported in hepatocytes (Wu et al., 2015). This provoked us to in-
vestigate the possible role of α7 receptor in the anti-HEV eﬀect of
deptropine. However, we found that the expression of this receptor is
very low in Huh7.5 cells (Fig. S3C). In addition, α-bungarotoxin, the
alpha-7 nicotinic receptor antagonist, has no eﬀect on HEV RNA level
and the anti-HEV eﬀect of deptropine is not aﬀected by the alpha-7
nicotinic receptor agonist nicotine (Fig. S3C), suggesting a α7 receptor-
independent antiviral mechanism of deptropine.
3.4. Deptropine inhibits HEV in an NF-κB-dependent manner
NF-κB plays a central role in promoting the expression of genes
involved in inﬂammation and is activated in various viral infections
(Tai et al., 2000). Moreover, the H1 antagonists are shown to inhibit
NF-κB activity (Roumestan et al., 2008). We thus sought to investigate
the potential role of NF-κB signaling in the deptropine-mediated anti-
HEV eﬀect. A lentiviral vector expressing the ﬁreﬂy luciferase gene
under control of the NF-κB promoter was transduced into Huh7.5 cells.
We found that inoculation of HEV particles signiﬁcantly activates the
NF-κB transcription activity, which correlates with enhanced viral re-
plication (Fig. 4A). In contrast to the potent NF-κB activator TNFα,
treatment with deptropine signiﬁcantly inhibited the NF-κB transcrip-
tion activity (Fig. 4B). Supplementation with TNFα signiﬁcantly atte-
nuated the inhibitory eﬀects of deptropine on NF-κB and anti-HEV ac-
tivity (Fig. 4C), suggesting the possible involvement of NF-κB in the
anti-HEV action of deptropine. To further evaluate the role of NF-κB on
HEV replication, we tested additional compounds targeting NF-κB ac-
tivity. The NF-κB activators, including betulinic acid and calcimycin,
signiﬁcantly inhibit HEV replication, whereas BAY11-7085 has no ef-
fect on HEV replication (Fig. S5).
To further conﬁrm the involvement of NF-κB in the antiviral eﬀect
of deptropine, wild type (WT), NF-κB knockout (NF-κB−/−) mouse
embryonic ﬁbroblasts (MEF) cells were used (Zhou et al., 2015). An
decreased HEV RNA was observed in the NF-κB −/− MEF cells in-
cubated with culture medium containing HEV particles compared with
its wild type, suggesting a supportive role of NF-κB for HEV replication.
Importantly, the anti-HEV eﬀect of deptropine was completely abol-
ished in the NF-κB−/− MEF cells (Fig. 4D), demonstrating the re-
quirement of NF-κB for the anti-HEV action of deptropine.
Activator protein 1 (AP-1) transcription activity is closely related to
NF-κB activity and has also been reported to be upregulated upon viral
infection. We found that HEV slightly increased AP-1 activity (Fig. S4A)
and deptropine could inhibit AP-1 activity (Fig. S4B). Moreover, asso-
ciated with the obtained results that histamine could partially reverse
the antiviral eﬀect of deptropine in the HEV infectious model (Fig. 3D),
the inhibitory eﬀects of either AP-1 or NF-κB transcriptional activity by
deptropine was also partially attenuated after adding histamine (Fig.
S4C).
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Fig. 2. Deptropine inhibits HEV replication in multiple cell models. (A) Huh7.5 cell based HEV replicon and infectious models were treated with indicated con-
centrations of deptropine for indicated time period before the measurement of HEV, and the untreated (CTR) group serve as control (set as 1) (n = 8). (B) 293T cell
based HEV replicon and infectious models were treated with indicated concentrations of deptropine for indicated time period before the measurement of HEV, and
the untreated (CTR) group serve as control (set as 1) (n = 8). (C) The 50% inhibitory concentration (IC50) and 50% cytotoxic concentration (CC50) of deptropine
against HEV replication in indicated cell lines were calculated using GraphPad Prism 5 software (n = 4–8). The IC50 of deptropine against genotype 1 (GT1) HEV
replication were calculated using GraphPad Prism 5 software (n = 5). (D) Treatment with 5 μM deptropine for 39 days retains anti-HEV eﬀect in Huh7.5 cell based
HEV infectious model. The untreated (CTR) group serve as control (set as 1) (n = 2). Western blot analysis of HEV capsid ORF2 protein levels in the Huh7.5 cell
based HEV infectious model treated with deptropine for 39 days. Data are presented as means ± SD. (*P < 0.05; **P < 0.01; ***P < 0.001).
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3.5. Caspase activity is required for the Anti-HEV eﬀect of deptropine
It has been reported that activation of NF-κB signaling negatively
regulate apoptosis by increasing the expression of anti-apoptotic genes,
such as survivin, which function mainly by binding to active caspase 3/
7 (Moghoofei et al., 2019). We found that the loss of NF-κB signaling
dramatically abolished the increase of caspase 3/7 activity induced by
deptropine (Fig. 4D). Concurrently, the expression of survivin was
signiﬁcantly reduced after treatment with deptropine (Fig. 4D).
Caspase activity is well-recognized for regulating viral infection. We
found that deptropine signiﬁcantly elevated cellular caspase 3 and 7
activity (Fig. 5A), accompanied with a low level of apoptosis induction
(Fig. S6A). Interestingly, HEV infection further augments the induction
of caspase activity by deptropine (Fig. 5A). Importantly, co-incubation
with Z-VAD-FMK, a general caspase inhibitor, attenuated the caspase
induction and anti-HEV activity of deptropine. Similar results were
observed in the combination of TNFα with Z-VAD-FMK (Fig. 5B).
Moreover, in line with the results of histamine on HEV (Fig. 3D),
treatment with histamine for 48 h signiﬁcantly increased the caspase
activity and decreased the activation of caspase induced by deptropine
(Fig. 5C). These data suggest the requirement of caspase activity for the
anti-HEV eﬀect of deptropine.
Interestingly, we found that in the presence of caspase 3 inhibitor,
treatment with deptropine even decreased the cellular caspase 3 and 7
activity (Fig. 5C), and this is accompanied by the increase of HEV RNA
when deptropine was added in combination with caspase 3 inhibitor
(Fig. 5D). Furthermore, treatment with other caspase inhibitors also
robustly abolished the anti-HEV eﬀect of deptropine, suggesting a
general role of caspase-mediated anti-HEV eﬀect of deptropine. Un-
expectedly, we found that all the caspase inhibitors signiﬁcantly re-
duced HEV RNA without aﬀecting cell viability (Figs. S6B and S6D),
indicating the basal caspase activity may support HEV replication.
Lastly, unlike the eﬀects on HEV, caspase inhibition barely reverse the
eﬀect of deptropine on HCV, suggesting a speciﬁc role of caspase
mediated anti-HEV eﬀect of deptropine (Fig. S6C). Taken together,
these data suggest that the basal caspase activity may support HEV
replication; however the deptropine-induced caspase activation may
contribute to its anti-HEV eﬀect.
3.6. Genetic silencing of RIPK1 restricts HEV replication and abolishes the
Anti-HEV eﬀect of deptropine
RIPK1 is positioned at the center of cell-fate ‘decisions’ by mod-
ulating the crosstalk between NF-κB and caspase activity (Oeckinghaus
et al., 2011). We examined the potential involvement of RIPK1. We
found that gene silencing of RIPK1 signiﬁcantly inhibited HEV re-
plication (Fig. 6A and B). Importantly, loss of RIPK1 completely blocked
the anti-HEV eﬀect of deptropine (Fig. 6C). The kinase activity of RIPK1
is essential in promoting apoptosis (Newton, 2015). Consistently, we
found that deptropine robustly induced phosphorylation of RIPK1 and
the phospho-PIPK1 is remarkably decreased in the presence of caspase
3 inhibitor (Fig. 6D). These results indicate that the kinase activity of
RIPK1 is essential in caspase-mediated anti-HEV eﬀect of deptropine
(Fig. 5D).
3.7. Deptropine antagonizes the Anti-HEV eﬀects of IFNα, but synergizes
ribavirin
Since IFNα and ribavirin are clinically used for treating chronic HEV
patients, we evaluated their combinatory eﬀects with deptropine. We
found that deptropine exhibited antagonistic eﬀect with IFNα (Fig. 7A),
but synergistic eﬀect with ribavirin (Fig. 7B). To explore the potential
mechanistic explanations, we evaluated their eﬀects on NF-κB activity.
Supportively, we found that IFNα but not ribavirin exerted strong in-
hibitory eﬀect on NF-κB activity (Fig. S7A). Although it has been re-
ported that IFNα is able to induce caspase activation (Apelbaum et al.,
2013), no increased caspase 3 and 7 activity was observed after treat-
ment with IFNα for 48 h in Huh7.5 cells (Fig. S7B). Furthermore, the
anti-HEV eﬀect of IFNα was not aﬀected in cells lacking RIPK1 (Fig.
S7C), which is distinct from the mechanism of deptropine.
Fig. 3. The anti-HEV eﬀect of deptropine is dispensable of the histamine pathway. (A) Chemical structures of the indicated compounds. (B) qRT-PCR analysis of HEV
RNA level in the Huh7.5 and 293T cell based HEV infectious models treated with indicated concentrations of diphenhydramine for 48 h. The untreated group serve as
control (set as 1) (n = 4). (C) qRT-PCR analysis of HEV RNA level in the Huh7.5 cell based HEV infectious model treated with indicated concentrations of
chlorcyclizine HCl (CCZ) for 48 h. The untreated group serve as control (set as 1) (n = 6). (D) Co-incubation of indicated concentrations of deptropine and histamine
in Huh7.5 and 293T for 48 h before testing the HEV-related luciferase. The untreated group serve as control (set as 1) (n = 5–6). Co-incubation of indicated
concentration of deptropine and histamine in Huh7.5 cell based HEV infectious model for 48 h before measurement of HEV RNA by qRT-PCR assay. The untreated
group serve as control (set as 1) (n = 4). The above data are means ± SD. (*P < 0.05; **P < 0.01).
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4. Discussion
Ribavirin monotherapy or in combination with PEG-IFNα is eﬀec-
tive for chronic hepatitis E. However, treatment failure frequently oc-
curs in a subset of patients (Debing et al., 2014). More importantly, a
large number of patients, especially acutely infected pregnant women,
are not eligible for this treatment. Drug repurposing allows rapid
identiﬁcation of new treatment from existing drugs that can dramati-
cally speed up the clinical implementation. For example, ribavirin was
initially approved for treating HCV but now is used as oﬀ-label treat-
ment for HEV (Kamar et al., 2014). Distinct from the empirical ap-
proach, recent development of high-throughput drug screening
technology has enabled unbiased identiﬁcation of potential treatment
from a large set of compounds. For example, screening of the FDA-ap-
proved drug libraries has led to the discoveries of potential therapies for
Ebola virus, HCV and Zika virus infections. Herein, by screening a li-
brary of FDA-approved drugs, we found that a histamine H1 receptor
antagonist deptropine potently inhibits HEV.
Among the four histamine receptors (H1, H2, H3, and H4), H1 re-
ceptor is the main regulator of acute inﬂammation. Accordingly, most
of the H1 antagonists function as inverse agonists, leading to the relief
of inﬂammation. An increased release of histamine from hepatic mast
cells has been reported in hepatitis (Francis and Meininger, 2010). In
this study, we found that supplementation with histamine has no eﬀect
Fig. 4. The anti-HEV eﬀect of deptropine requires its inhibition on NF-κB activity. (A) The Huh7.5 cell based NF-κB reporter model was inoculated with culture
medium containing HEV particles. After 3 days inoculation, the medium was changed to normal cell culture medium without HEV particles. TNFα treatment serves as
a positive control. The untreated mock group serves as control (set as 1). The NF-κB luciferase was measured at indicated time points (n= 8–12). qRT-PCR analysis of
the HEV RNA level in the mock group or HEV-infected group at indicated time points. The HEV RNA tested on 4, 5, 6 days are relative to the HEV RNA on day 3 (set
as 1) (n=4). (B) The Huh7.5 cell based NF-κB reporter model was treated with indicated agents for 24 h before testing the NF-κB luciferase value. The untreated
group serves as control (set as 1) (n= 6). (C) The Huh7.5 cell HEV infectious model was treated with indicated agents for 24 h before testing NF-κB luciferase value
and for 48 h before testing HEV RNA level by qRT-PCR assay. Data in deptropine-treated group were presented relative to the untreated control group (set as 1). Data
in the combination group of deptropine with TNFα were presented relative to TNFα-solely treated group (set as 1) (n= 6–8). (D) The wild type (WT) and NF-κB
knockout (NF-κB−/−) mouse embryonic ﬁbroblast (MEF) cells were treated with deptropine, and the HEV RNA level were measured by qRT-PCR assay after 48 h
treatment. The untreated WT group serves as control (set as 1) (n=8). The wild type (WT) and NF-κB knockout (NF-κB−/−) mouse embryonic ﬁbroblasts (MEF)
cells were inoculated with HEV particles (1.5× 106 HEV RNA copies/ml) and treated with indicated agents. Data in WT MEF was presented relative to the non-
treated WT group (set as 1). Data in NF-κB−/− MEF were presented relative to the untreated NF-κB−/− MEF group (set as 1) (n = 6). Huh7.5 cells were treated
with indicated concentrations of deptropine. The RNA level of Survivin was measured by qRT-PCR assay after 48 h treatment. The untreated group serves as control
(set as 1) (n = 6). The above data are means ± SD. (*P < 0.05; **P < 0.01; ***P < 0.001).
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on HEV replication in a subgenomic replicon that only mimics viral
replication due to the lack of ORF2 capsid protein. However, histamine
dose-dependently inhibits HEV infection in the infectious model with
the full life-cycle, suggesting multiple interaction between HEV and
histamine signaling. Previous studies have reported the inhibition of the
entry of Ebola/Marburg virus (Cheng et al., 2015) and HCV by H1
antagonists (Cheng et al., 2015). However, the antiviral eﬀect of H1
antagonist seems not require the H1 receptor (He et al., 2015).
It has been reported that H1 antagonist could regulate the tran-
scription factor NF-κB and caspase activity (Haas et al., 2018). This
coordinately modulates the inﬂammatory microenvironment, resulting
in enhancement or antagonism of the host antiviral defense. Increased
NF-κB activity induces the transcription of genes promoting cell sur-
vival (Schmitz et al., 2014). On the contrary, activation of caspases is
thought to counteract the pro-survival role of NF-κB. Of note, RIPK1
actively modulates the crosstalk between caspase and NF-κB signaling.
Viruses have developed sophisticated strategies to evade host defense.
Dengue virus and inﬂuenza virus activate NF-κB to support their re-
plication (Cassens et al., 2003; Nimmerjahn et al., 2004). For hepatitis
viruses, HCV was reported to increase NF-kB and AP-1 activation,
which was further augmented by the presence of hepatitis B virus X
protein (Kanda et al., 2006). We found that inoculation of HEV particles
increases NF-κB activity. In addition, we have demonstrated that the
basal NF-κB activity serves as a supportive factor for HEV replication. In
patients, liver biopsies from pregnant women infected with HEV who
developed fulminant hepatic failure (FHF) have higher transcriptional
activity of NF-kB compared to those from nonpregnant women or
pregnant women infected HEV without development of FHF (Prusty
et al., 2007). Consistent with a recent study (Lenggenhager et al.,
2017), we found that the presence of HEV ORF2 protein in cell nucleus
(Fig. S4D). We thus speculate the possibility that nuclear ORF2 may
play a role in HEV-mediated regulation of NF-κB transcription. In
contrast, HEV ORF3 protein has been reported to suppress TLR3-in-
duced NF-κB activity (He et al., 2016). Thus, the interactions of HEV
with NF-κB are multifaceted, requiring further clariﬁcation.
There are mutual interactions between caspase activation and viral
infection (Saelens et al., 2001). Several viruses express proteins tar-
geted by the caspase protease and cleavage of these proteases results in
inhibition of apoptosis (Connolly and Fearnhead, 2017; Richard and
Tulasne, 2012). HCV infection induces caspase activation to cleave the
Fig. 5. Inhibition of caspase activity reverses the anti-HEV eﬀect of deptropine. (A) Huh7.5 cell based HEV infectious model was treated with indicated agents for
48 h before subjected to caspase 3/7 activity analysis. The untreated mock group serves as control (set as 1) (n = 8). (B) Huh7.5 cell based HEV infectious and
replicon models were treated with indicated agents, alone or in combination. After 48 h treatment, samples were subjected to qRT-PCR analysis. Data in deptropine
or TNFα solely treated groups were presented relative to the untreated group (set as 1). Data in the combination group of deptropine or TNFα with Z-VAD-FMK were
presented relative to Z-VAD-FMK solely treated group (set as 1) (n = 7–9). (C) Huh7.5 cells were treated with indicated agents for 48 h before being subjected to
caspase 3/7 activity analysis. The untreated group serves as control (set as 1) (n = 4–5). (D) Huh7.5 cell based HEV infectious model was treated with indicated
agents, alone or in combination. After 48 h treatment, samples were subjected to qRT-PCR analysis. Data in deptropine solely treated group were presented relative to
the untreated group (set as 1). Data in combination group of deptropine with caspase 1 or caspase 3 were presented relative to caspase 1 or caspase 3 solely treated
group (set as 1) (n = 6–9). Huh7.5 cell based HEV infectious model was treated with indicated agents, alone or in combination. After 48 h treatment, samples were
subjected to qRT-PCR analysis. Data in deptropine solely treated group were presented relative to the untreated group (set as 1). Data in combination group of
deptropine with caspase 8 or caspase 9 were presented relative to caspase 8 or caspase 9 solely treated group (set as 1) (n = 5–10). The above data are means ± SD.
(*P < 0.05; **P < 0.01; ***P < 0.001).
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viral nonstructural protein 5A, which subsequently translocates to nu-
cleus to enhance the transcription of several NF-κB target genes to in-
hibit apoptosis (Jiang et al., 2015). However, some viruses can beneﬁt
from caspase activation. Inﬂuenza A virus and papillomaviruses require
caspase activity for eﬃcient replication (Moody et al., 2007; Ozawa
et al., 2007). Recent evidence indicate that HEV infection is associated
with caspase activation (Yang et al., 2018). The release of cytochrome c
from mitochondria is a key event to activate caspase. A previous study
has reported that HEV prevents the release of cytochrome c induced by
staurosporine, suggesting a negative regulation of caspase activation by
HEV infection (Moin et al., 2007). Consistently, our recent study has
shown that HEV is able to block ionomycin-induced MPTP opening (Qu
et al., 2019), which is a vital process to activate caspase. In this study,
we found that blocking of the excessive caspase activation induced by
deptropine could reverse its anti-HEV eﬀect. Counterintuitively, the
basal caspase activity may support HEV replication as inhibition of
caspase activity leads to reduction of HEV RNA.
RIPK1 is a key determinant of cell survival or death through its
scaﬀold properties or kinase activity, respectively (Kondylis and
Pasparakis, 2019; Lafont et al., 2018). This essentially involves the
crosstalk between caspase and NF-κB signaling. We found that gene
silencing of RIPK1 dramatically inhibits HEV replication. Importantly,
loss of RIPK1 abolished the anti-HEV eﬀect of deptropine. Interestingly,
deptropine robustly induces RIPK1 phosphorylation and this eﬀect can
be inhibited by caspase inhibitor. These results have indicated the im-
portance of RIPK1 in mediating the anti-HEV action of deptropine.
However, the exact role of the scaﬀold property or/and kinase activity
of RIPK1 in this process remains to be further clariﬁed.
In summary, we have identiﬁed deptropine as a potent anti-HEV
agent. The anti-HEV activity of deptropine involves the NF-κB-RIPK1-
caspase axis, but the detailed working mechanisms remain to be further
investigated. Given that deptropine is a safe and cheap drug that has
been widely used to treat asthmatic symptoms in the clinic, it is war-
ranted to evaluate its anti-HEV eﬃcacy in future clinical studies. By
implementation of these results in the clinical setting, this may re-
volutionize the current management of hepatitis E and represent as a
milestone in response to the global call towards the elimination of he-
patitis B and C by 2030.
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